source
- Zanidatamab shows strong single-agent activity in HER2-positive gastric and biliary cancersZanidatamab, a dual HER2-binding antibody, demonstrated notable efficacy as a single agent in studies of gastric and biliary tract cancers. The activity was described as striking, suggesting that…
- Entrada Therapeutics' next-gen Duchenne drug fails early trial, raising competitive concernsEntrada Therapeutics reported that its next-generation exon-skipping therapy for Duchenne muscular dystrophy did not meet efficacy endpoints in an early-stage study. The trial, which evaluated the…